Status:
COMPLETED
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Vetera...
Eligibility Criteria
Inclusion
- Participants who fulfill criteria for initial staging or restaging as outlined below:
- Initial treatment strategy decisions (initial staging)
- All participants with histologically proven prostate cancer or strong suspicion of prostate adenocarcinoma based on very high PSA levels (\>50 ng/mL) who require an initial treatment/management decision who may be candidate for any of the following strategies:
- A) Surgery B) External radiation therapy (RT) C) Other focal therapies D) Systemic medical treatment E) Watchful waiting
- Assessment for Subsequent treatment strategy (restaging), any of the following:
- A) Participants with biochemical recurrence who are potential candidates for any salvage treatment. Biochemical recurrence is defined by rising PSA after definitive therapy with prostatectomy or radiation therapy, as any of the following:
- Post radical prostatectomy (RP): PSA equals to or greater than 0.2 ng/mL measured more than 6 weeks after RP
- Post-radiation therapy : Nadir + greater than or equal to 2 ng/mL rise in PSA B) Participants with known prostate cancer who undergo restaging because of new symptoms C) Participants with known metastatic prostate cancer who undergo restaging because of rising PSA with negative or inconclusive conventional imaging D) Participants with known prostate cancer who are treated medically or with RLT in whom response to treatment is assessed
- Capability to provide written informed consent
- Able to remain still for duration of each imaging procedure (about 30 minutes) \* Participants may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
Exclusion
- Less than 18 years-old at the time of radiotracer administration
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
- Inability to provide written informed consent
Key Trial Info
Start Date :
April 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
239 Patients enrolled
Trial Details
Trial ID
NCT04390880
Start Date
April 7 2020
End Date
August 31 2021
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073